Promis Neurosciences Total Assets 2017-2024 | PMN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Promis Neurosciences total assets from 2017 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Promis Neurosciences total assets from 2017 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$152.1B
Vertex Pharmaceuticals (VRTX)	$120.6B
Bristol Myers Squibb (BMY)	$120.1B
Gilead Sciences (GILD)	$115.4B
CSL (CSLLY)	$89B
Regeneron Pharmaceuticals (REGN)	$82.4B
GSK (GSK)	$70.7B
Argenex SE (ARGX)	$37.2B
Alnylam Pharmaceuticals (ALNY)	$32.6B
BioNTech SE (BNTX)	$28.4B
Biogen (BIIB)	$23.4B
Illumina (ILMN)	$22.9B
BeiGene (BGNE)	$20.9B
Moderna (MRNA)	$16.6B
Incyte (INCY)	$14.4B
Genmab (GMAB)	$14.2B
Insmed (INSM)	$13.4B
Sarepta Therapeutics (SRPT)	$12.7B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$12B
Vaxcyte (PCVX)	$11.8B
Exact Sciences (EXAS)	$11.5B
Exelixis (EXEL)	$10.4B
QIAGEN (QGEN)	$9.9B
Revolution Medicines (RVMD)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$9.3B
Intra-Cellular Therapies (ITCI)	$9.1B
Repligen (RGEN)	$8.4B
Ascendis Pharma (ASND)	$8.3B